MARKET

CRDF

CRDF

Cardiff Oncology Inc
NASDAQ
1.650
0.000
0.00%
After Hours: 1.640 -0.01 -0.61% 18:29 03/31 EDT
OPEN
1.640
PREV CLOSE
1.650
HIGH
1.680
LOW
1.620
VOLUME
78.76K
TURNOVER
0
52 WEEK HIGH
3.410
52 WEEK LOW
1.130
MARKET CAP
73.72M
P/E (TTM)
-1.8558
1D
5D
1M
3M
1Y
5Y
Analysts Offer Insights on Healthcare Companies: Cardiff Oncology (CRDF), Evotec AG (EVO) and Harpoon Therapeutics (HARP)
TipRanks · 3d ago
BRIEF-Cardiff Oncology Announces First Patient Dosed In Mid-stage Trial Of Colorectal Cancer Drug
Reuters · 4d ago
Cardiff Oncology (CRDF) Receives a Buy from Robert W. Baird
TipRanks · 03/13 06:15
BRIEF-Cardiff Oncology Inc Confirms It Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank
Reuters · 03/10 21:53
Unusual Put Option Trade in Cardiff Oncology (CRDF) Worth $52.50K
NASDAQ · 03/10 20:10
Analysts’ Top Healthcare Picks: Cardiff Oncology (CRDF), Aclaris Therapeutics (ACRS)
TipRanks · 03/07 11:30
--HC Wainwright Adjusts Price Target on Cardiff Oncology to $15 From $14, Keeps Buy Rating
--HC Wainwright Adjusts Price Target on Cardiff Oncology to $15 From $14, Keeps Buy Rating
MT Newswires · 03/07 09:13
Cardiff Oncology GAAP EPS of -$0.89 beats by $0.05, revenue of $0.39M beats by $0.12M
Seeking Alpha · 03/02 21:36
More
About CRDF
Cardiff Oncology, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies across a range of cancers with unmet medical needs. The Company is focused on tumor vulnerabilities with treatment combinations of onvansertib, its selective PLK1 inhibitor, and standard of care (SoC) therapeutics. The Company has five ongoing clinical trials of onvansertib, including two trials (TROV-054 and ONSEMBLE) in second-line treatment in patients with KRAS-mutated Metastatic Colorectal Cancer (mCRC), one trial in second-line treatment in patients with Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC), and two investigator-initiated trials in patients with unresectable locally advanced or metastatic Triple Negative Breast Cancer (TNBC) and relapsed Small Cell Lung Cancer (SCLC). The Company has third-party manufacturers and distributors to supply and distribute onvansertib used in its clinical studies and nonclinical development programs.

Webull offers kinds of Cardiff Oncology Inc stock information, including NASDAQ:CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.